MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment

    P. Dowell, K. Lyons, R. Pahwa (Kansas City, KS, USA)

    Objective: To assess the safety and efficacy of carbidopa/levodopa enteral suspension (CLES) in Parkinson’s disease (PD) patients with cognitive impairment. Background: As Parkinson’s Disease progresses,…
  • 2017 International Congress

    Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations

    J. Mitsui, K. Koguchi, T. Momose, M. Takahashi, T. Matsukawa, T. Yasuda, S.-i. Tokushige, H. Ishiura, J. Goto, S. Nakazaki, T. Kondo, H. Ito, Y. Yamamoto, S. Tsuji (Tokyo, Japan)

    Objective: To present the detailed clinical features of a patient with familial MSA carrying compound heterozygous COQ2 mutations and report the outcome of a high-dose ubiquinol…
  • 2017 International Congress

    How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?

    E. Okuyucu, M. Uzel, S. Colakoglu Yesıldag, M. Guntel (Hatay, Turkey)

    Objective: To clarify the possible associations of  levodopa / benserazidehydrochloride usage and  skin rashes. Background:   Levodopa/benserazide hydrochloride   is one of the best dopaminergic drug used…
  • 2017 International Congress

    Parkinson Syndrome associated with inositol-1,4,5-triphosphate receptor antigen type 1 (ITPR1) antibodies

    B. Wimmer, K. Fuchs, U. Bogdahn, A. Heimeroth (Regensburg, Germany)

    Objective: To illustrate an unusual clinical presentation of Parkinson´s disease (PD) that was effectively treated with immune adsorption. Background: Autoimmune mediated movement disorders may be…
  • 2017 International Congress

    Unusual facial synkinesia after Bell’s palsy: interactive Marin-Amat syndrome proven by surface electromyogram, successfully treated with low dose botulinum toxin A.

    H. Mori (Kurashiki, Japan)

    Objective: To clarify unusal facial synkinesia by using surface electromyogram and botulinum toxin A. Background: Marin-Amat syndrome is a facial synkinesis manifesting as involuntary eyelid…
  • 2017 International Congress

    A novel cause for unpredictable response to levodopa

    J. Staisch, G. Bakis, J. Nutt (Portland, OR, USA)

    Objective: [To describe a novel cause for unpredictable response to levodopa] Background: A fluctuating response to levodopa is common in advanced Parkinson’s disease and can…
  • 2017 International Congress

    Treatment of secondary movement disorders related to midbrain cavernomas

    K. Karpinska, A. Smolanka (Uzhgorod, Ukraine)

    Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…
  • 2017 International Congress

    Infusion Rate Dependent Acute Neuropathic Pain with Duopa™ in a Patient with Parkinson’s disease and Pre-Existing Neuropathy

    A. Shukla, R. Govindarajan, I. Asher (Columbia, MO, USA)

    Objective: To report a case of rate dependent acute neuropathic pain with Duopa™ in a Parkinson’s patient with preexisting neuropathy. Background: Subacute to chronic neuropathy…
  • 2017 International Congress

    Prevalence of tremor in Multiple Sclerosis in Isfahan, Iran

    M. Salari, M. Etemadifar, O. Mirmosayyeb (Isfahan, Islamic Republic of Iran)

    Objective: To evaluate prevalence of tremor in Multiple sclerosis in Isfahan Background: Multiple sclerosis (MS) is demyelinating disease of central nervous system (CNS), affecting mostly…
  • 2017 International Congress

    Ultrasonography-guided Botulinum Toxin Type-A Injection in Tremor. An open-label Study

    H. Shehata, N. Shalaby, M. Basheer, A. Elmazny, S. Eljaafary (Cairo, Egypt)

    Objective: To assess the role of ultrasound-guided (US) Onabotulinumtoxin-A (BoNT-A) injections for various types of hand and head tremor. Background: Focal treatment of head and…
  • « Previous Page
  • 1
  • …
  • 1445
  • 1446
  • 1447
  • 1448
  • 1449
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley